• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database
CONCLUSION: CLL patients with AF are at a significantly increased risk of all-cause mortality, cardiac-related mortality, and stroke. For this population, a multidisciplinary approach should be orchestrated for better management and outcomes.PMID:34598909 | DOI:10.1016/j.clml.2021.08.006
Source: Clinical Lymphoma and Myeloma - October 2, 2021 Category: Cancer & Oncology Authors: Mohammad Ammad Ud Din Samarthkumar Thakkar Harsh Patel Hassan Saeed Syed Ather Hussain Hania Liaqat Aneeqa Zafar Sourbha S Dani Sarju Ganatra Faiz Anwer Source Type: research

Cancers, Vol. 13, Pages 4012: Atrial Fibrillation after Lung Cancer Surgery: Prediction, Prevention, and Anticoagulation Management
rdinale Atrial fibrillation (AF) is a common complication of the early postoperative period of various types of surgery, including that for lung cancer. Although induced by the homeostatic alterations related to surgery, there is evidence that it is not a mere stand-alone transitory event, but it represents a relevant complication of surgery, bearing considerable prognostic consequences. Different methods have therefore been explored to predict the occurrence of postoperative atrial fibrillation (POAF) and prevent it. In particular, the age among clinical factors, and N-terminal prohormone of brain natriuretic peptide ...
Source: Cancers - August 9, 2021 Category: Cancer & Oncology Authors: Gennaro Semeraro Carlo Meroni Carlo Cipolla Daniela Cardinale Tags: Review Source Type: research

Cancers, Vol. 13, Pages 4012: Atrial Fibrillation after Lung Cancer Surgery: Prediction, Prevention and Anticoagulation Management
rdinale Atrial fibrillation (AF) is a common complication of the early postoperative period of various types of surgery, including that for lung cancer. Although induced by the homeostatic alterations related to surgery, there is evidence that it is not a mere stand-alone transitory event, but it represents a relevant complication of surgery, bearing considerable prognostic consequences. Different methods have therefore been explored to predict the occurrence of postoperative atrial fibrillation (POAF) and prevent it. In particular, the age among clinical factors, and N-terminal prohormone of brain natriuretic peptide ...
Source: Cancers - August 9, 2021 Category: Cancer & Oncology Authors: Gennaro Carmine Semeraro Carlo Ambrogio Meroni Carlo Maria Cipolla Daniela Maria Cardinale Tags: Review Source Type: research

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Implementation of Oral Anticoagulation Treatment Guidelines in Patients with Newly Diagnosed Atrial Fibrillation
CONCLUSION: Despite the increasing OAC treatment rates among high risk AF patients, mainly attributed to the expanding DOAC use, OAC treatment scope is still far from optimal.PMID:33982796 | DOI:10.1111/bcp.14899
Source: Clinical Colorectal Cancer - May 13, 2021 Category: Cancer & Oncology Authors: Anat Arbel Zomoroda Abu-Ful Meir Preis Shai Cohen Walid Saliba Source Type: research

Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?
ConclusionAC did not seem to influence the incidence of ICH in patients with glioblastoma or brain metastases within follow up of just under 9  months.
Source: Journal of Neuro-Oncology - March 5, 2021 Category: Cancer & Oncology Source Type: research

Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Conclusion: In cancer patients with AF, NOAC were associated with significant reduced IS/SE, major bleeding, and ICH compared to warfarin.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Victor Chien-Chia Wu, Chun-Li Wang, Yu-Tung Huang, Wen-Ching Lan, Michael Wu, Chang-Fu Kuo, Shao-Wei Chen, Pao-Hsien Chu, Ming-Shien Wen, Chi-Ching Kuo, Shang-Hung Chang Tags: Research Paper Source Type: research

Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population ‐based propensity score matching study
ConclusionThis nationwide population ‐based study revealed that ADT was not associated with cerebral infarction after adjusting for potential confounders.
Source: Cancer Medicine - June 9, 2019 Category: Cancer & Oncology Authors: Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jae Hyun Bae, Jae Young Park Tags: ORIGINAL RESEARCH Source Type: research

Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies
AbstractPurpose of ReviewThe anticoagulation strategies for various cardiac-specific pathologies including atrial fibrillation are changing. Applying these strategies in patients with concomitant active cancer requires additional considerations. Here, we review the most recent changes in the anticoagulation management of common cardiac diseases and their application in cancer patients.Recent FindingsThere are a range of indications for therapeutic anticoagulation in cancer patients including venous thromboembolism (VTE), atrial fibrillation/flutter (AF/AFL), prosthetic heart valves, and intracardiac thrombi. Certain cancer...
Source: Current Oncology Reports - April 3, 2019 Category: Cancer & Oncology Source Type: research

AFib patients with cancer history less likely to see cardiologist, fill prescriptions
(American College of Cardiology) Atrial fibrillation (AFib) patients with a history of cancer are less likely to see a cardiologist or fill anticoagulant prescriptions compared with AFib patients who never had cancer, according to a study in the Journal of the American College of Cardiology. By not filling and taking prescribed medication, these patients are potentially putting themselves at increased risk of stroke.
Source: EurekAlert! - Cancer - October 8, 2018 Category: Cancer & Oncology Source Type: news

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.
Conclusion: In ROCKET AF, a history of cancer was associated with a higher risk of bleeding and non-cardiovascular death, but not ischemic events. The relative efficacy and safety of rivaroxaban compared with warfarin were not significantly different in patients with and without a history of cancer. The results of this study are exploratory and should be taken in context of the study population, which may not be generalizable to those with advanced malignancy. Further investigation is needed to understand optimal anticoagulation strategies in patients with AF and cancer. PMID: 30219887 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C Tags: Eur Heart J Qual Care Clin Outcomes Source Type: research

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.
Authors: Cullell N, Carrera C, Muiño E, Torres N, Krupinski J, Fernandez-Cadenas I Abstract Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular events and recurrence in patients with atrial fibrillation (AF) and cardioembolic stroke. We conducted a literature search to review the current state of OAs pharmacogenomics, focusing on Genome Wide Association Studies (GWAs) in patients treated with vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). VKAs: Warfarin, acenocoumarol, fluindione and phenprocoumon have long been used, but their interindividual variability and narrow ...
Source: Oncotarget - July 20, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score-a nationwide cohort study.
Conclusions: The impact of AF on risk of ischemic stroke was attenuated with advancing CHA2DS2-VASc score in patients with cancer. PMID: 29484138 [PubMed]
Source: Oncotarget - February 28, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Influenza vaccination might reduce the risk of ischemic stroke in patients with atrial fibrillation: A population-based cohort study.
Conclusions: Influenza vaccination might exert a dose-response effect against ischemic stroke in patients with AF who have risk factors for ischemic stroke by reducing the incidence of ischemic stroke, particularly in those aged 65-74 and ≥75 y. PMID: 29348857 [PubMed]
Source: Oncotarget - January 21, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Pages: 1  2  3  4  5  6  7